JOHN VIERLING to PPAR alpha
This is a "connection" page, showing publications JOHN VIERLING has written about PPAR alpha.
Connection Strength
0.221
-
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354.
Score: 0.169
-
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 02 29; 390(9):795-805.
Score: 0.051